InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,344.16
(
0.47%
)
US TECH 100
18,089.20
(
0.40%
)
Dow Jones
39,497.54
(
0.13%
)
Brent Oil
80.05
(
1.07%
)
Bitcoin
58,828.30
(
0.18%
)
Post# of 252823
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 120253
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 231760

Thursday, 07/30/2020 4:14:35 PM

Thursday, July 30, 2020 4:14:35 PM

Post# of 252823
GILD 2Q20 HCV sales=$448M, -39% QoQ, -41% YoY. The 2Q20 geographic breakdown was: US $220M; EU $70M; RoW $158M.

During 2Q20, the COVID-19 pandemic greatly reduced HCV patient visits and hence new-patient starts, worldwide. GILD’s worldwide HCV patient starts in 2Q20 (CC slide #16) were 25K vs 45K in 1Q20 (decreasing from 29K to 17K in the US).

PR:
http://investors.gilead.com/news-releases/news-release-details/gilead-sciences-announces-first-quarter-2020-financial-results

CC slides:
http://investors.gilead.com/static-files/cd67608e-573e-4a6a-8131-aee5b9e2453e

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up